SK Bioscience Co Ltd
KRX:302440
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
44 700
73 300
|
| Price Target |
|
We'll email you a reminder when the closing price reaches KRW.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
SK Bioscience Co Ltd
SK Bioscience Co Ltd
PP&E Net
SK Bioscience Co Ltd
PP&E Net Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | PP&E Net | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
SK Bioscience Co Ltd
KRX:302440
|
PP&E Net
₩315.9B
|
CAGR 3-Years
19%
|
CAGR 5-Years
13%
|
CAGR 10-Years
N/A
|
|
|
Celltrion Inc
KRX:068270
|
PP&E Net
₩1.2T
|
CAGR 3-Years
9%
|
CAGR 5-Years
6%
|
CAGR 10-Years
3%
|
|
|
Green Cross Corp
KRX:006280
|
PP&E Net
₩932.9B
|
CAGR 3-Years
6%
|
CAGR 5-Years
8%
|
CAGR 10-Years
9%
|
|
|
H
|
Hugel Inc
KOSDAQ:145020
|
PP&E Net
₩149.2B
|
CAGR 3-Years
19%
|
CAGR 5-Years
17%
|
CAGR 10-Years
N/A
|
|
|
P
|
PharmaResearch Co Ltd
KOSDAQ:214450
|
PP&E Net
₩138.4B
|
CAGR 3-Years
12%
|
CAGR 5-Years
15%
|
CAGR 10-Years
N/A
|
|
|
Alteogen Inc
KOSDAQ:196170
|
PP&E Net
₩19.3B
|
CAGR 3-Years
-14%
|
CAGR 5-Years
4%
|
CAGR 10-Years
N/A
|
|
SK Bioscience Co Ltd
Glance View
SK bioscience Co., Ltd. engages in the development and distribution of bio and vaccine products. The company is headquartered in Seongnam, Gyeonggi-Do. The company went IPO on 2021-03-18. The firm's main products include vaccines such as SKYCellflu and Rotatech. The firm also sells infusion solutions. In addition, the Company engages in technology export business. The firm sells its products in domestic and overseas markets.
See Also
What is SK Bioscience Co Ltd's PP&E Net?
PP&E Net
315.9B
KRW
Based on the financial report for Dec 31, 2023, SK Bioscience Co Ltd's PP&E Net amounts to 315.9B KRW.
What is SK Bioscience Co Ltd's PP&E Net growth rate?
PP&E Net CAGR 5Y
13%
Over the last year, the PP&E Net growth was 8%. The average annual PP&E Net growth rates for SK Bioscience Co Ltd have been 19% over the past three years , 13% over the past five years .
You don't have any saved screeners yet
